Biodistribution and Radiation Dosimetry of Intraperitoneally Administered ¹²⁴I-Omburtamab in Patients with Desmoplastic Small Round Cell Tumors.

ABSTRACT: The aim of this study was to assess the pharmacokinetics, biodistribution, and radiation dosimetry of ¹²⁴I-omburtamab administered intraperitoneally in patients with desmoplastic small round cell tumor. Methods: Eligible patients diagnosed with desmoplastic small round cell tumor with peritoneal involvement were enrolled in a phase I trial of intraperitoneal radioimmunotherapy with ¹³¹I-omburtamab. After thyroid blockade and before radioimmunotherapy, patients received approximately 74 MBq of ¹²⁴I-omburtamab intraperitoneally. Five serial PET/CT scans were obtained up to 144 h after injection. Multiple blood samples were obtained up to 120 h after injection. Organ-absorbed doses were calculated with OLINDA/EXM. Results: Thirty-one patients wer

SUBMITTER: Grkovski M 

PROVIDER: S-EPMC9258578 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature